CMH Wealth Management LLC decreased its position in SPDR S&P Biotech ETF (NYSEARCA:XBI – Free Report) by 40.8% in the fourth quarter, Holdings Channel reports. The firm owned 38,135 shares of the exchange traded fund’s stock after selling 26,294 shares during the period. CMH Wealth Management LLC’s holdings in SPDR S&P Biotech ETF were worth $3,434,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors also recently bought and sold shares of the company. Healthcare of Ontario Pension Plan Trust Fund raised its position in SPDR S&P Biotech ETF by 198.6% during the 3rd quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 9,229,000 shares of the exchange traded fund’s stock valued at $911,825,000 after purchasing an additional 6,138,000 shares in the last quarter. Clal Insurance Enterprises Holdings Ltd purchased a new position in shares of SPDR S&P Biotech ETF during the third quarter valued at $141,284,000. Affinity Asset Advisors LLC raised its holdings in shares of SPDR S&P Biotech ETF by 105.4% in the second quarter. Affinity Asset Advisors LLC now owns 37,550 shares of the exchange traded fund’s stock valued at $3,481,000 after acquiring an additional 737,550 shares in the last quarter. Assetmark Inc. lifted its stake in SPDR S&P Biotech ETF by 72,653.0% in the third quarter. Assetmark Inc. now owns 589,299 shares of the exchange traded fund’s stock worth $58,223,000 after acquiring an additional 588,489 shares during the period. Finally, Sivik Global Healthcare LLC bought a new position in SPDR S&P Biotech ETF during the 3rd quarter worth about $29,640,000.
SPDR S&P Biotech ETF Stock Performance
NYSEARCA XBI opened at $87.97 on Tuesday. SPDR S&P Biotech ETF has a one year low of $81.14 and a one year high of $105.47. The company has a market capitalization of $6.71 billion, a price-to-earnings ratio of 11.47 and a beta of 1.11. The company’s 50-day simple moving average is $93.78 and its two-hundred day simple moving average is $96.96.
About SPDR S&P Biotech ETF
SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.
Recommended Stories
- Five stocks we like better than SPDR S&P Biotech ETF
- 3 Monster Growth Stocks to Buy Now
- 3 Stocks to Gain From Donald Trump’s External Revenue Service
- How to Invest in Biotech Stocks
- AMD: Loop Capital’s Buy Rating Reinforces Investor Confidence
- Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
- Momentum Is Building for Qualcomm to Have a Strong Run in 2025
Want to see what other hedge funds are holding XBI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SPDR S&P Biotech ETF (NYSEARCA:XBI – Free Report).
Receive News & Ratings for SPDR S&P Biotech ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SPDR S&P Biotech ETF and related companies with MarketBeat.com's FREE daily email newsletter.